Castle Biosciences Receives Assay Approval From The New York State Department Of Health For Its TissueCypher Barrett's Esophagus Test

Castle Biosciences獲得紐約州衛生部對其TissueCypher巴雷特食道測試的檢測批准

Benzinga · 01/06 20:04

TissueCypher is the first AI-driven precision medicine test designed to predict a patient's individual risk of progression from Barrett's esophagus (BE) to esophageal cancer.

TissueCypher是第一個基於人工智能的精準醫學測試，旨在預測患者從巴雷特食道（BE）發展爲食道癌的個體風險。

With this approval, all of the tests in Castle's dermatology, gastroenterology and ophthalmology portfolios, as well as its clinical laboratories in Phoenix and Pittsburgh, are now approved by the state of New York.

隨着這一批准，Castle公司在皮膚病學、胃腸病學和眼科醫療領域的所有測試，以及其在菲尼克斯和匹茲堡的臨牀實驗室，現在都獲得了紐約州的批准。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。

Castle Biosciences Receives Assay Approval From The New York State Department Of Health For Its TissueCypher Barrett's Esophagus Test

Castle Biosciences Receives Assay Approval From The New York State Department Of Health For Its TissueCypher Barrett's Esophagus Test

風險及免責聲明

聲明